NCT02295826View on ClinicalTrials.gov

Dabigatran Following Transient Ischemic Attack and Minor Stroke

PHASE2CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 18, 2018

Study Completion Date

December 18, 2018

Conditions
Transient Ischemic AttackMinor Ischemic Stroke
Interventions
DRUG

Dabigatran

Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.

DRUG

Acetylsalicylic acid

participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day

Trial Locations (6)

T2N 2T9

University of Calgary, Calgary

T6G 2B7

University of Alberta, Edmonton

T6L 5X8

Grey Nuns Hospital, Edmonton

V5Z 1M9

Vancouver Stroke Program, Vancouver

L8L 0A6

Hamilton Health Sciences, Hamilton

H2L 4M1

Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montreal

All Listed Sponsors
lead

University of Alberta

OTHER

NCT02295826 - Dabigatran Following Transient Ischemic Attack and Minor Stroke | Biotech Hunter | Biotech Hunter